Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 10, Issue 4, Pages 465-480Publisher
TAYLOR & FRANCIS AS
DOI: 10.1586/ERM.10.31
Keywords
angiogenesis; bone marrow microenvironment; bone turnover; extracellular matrix; monoclonal gammopathy of unknown significance; multiple myeloma; multiplex ELISA; osteoclast; proteoglycans; RANK ligand; Wnt signaling
Categories
Funding
- Intramural NIH HHS [Z01 DE000380-25] Funding Source: Medline
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000380] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000380] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Multiple myeloma (MM) is the second most common hematological malignancy, with an overall survival of 4-6 years. It is always preceded by a premalignant stage called monoclonal gammopathy of unknown significance (MGUS). Importantly, at this time we lack reliable predictors to determine who will progress from MGUS to MM, and who will remain stable. The bone marrow microenvironment plays a key role in myelomagenesis (growth, survival and migration of malignant plasma cells). In the present review, we summarize and discuss our current understanding of the bone marrow microenvironment and its compartments in relation to myelomagenesis. Although it remains to be proven, we believe that an improved characterization of the cellular constituents, the extracellular matrix components and the soluble factors of the bone marrow could open up novel avenues to better understand underlying mechanisms of the transformation from MGUS to MM. Ultimately, this will lead to the development of early treatment of high-risk precursor disease aimed to delay/prevent MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available